Nitro aromatic ring substituted imidazopyrazine compound as well as preparation method and application thereof
By developing nitro aromatic ring-substituted imidazolopyrazine compounds as NanoLuc bioluminescence probes, the problem of lack of effective nitroreductase probes in the prior art was solved, and efficient detection and imaging of NTR activity was achieved, and the Application of bioluminescence technology in disease diagnosis and treatment.
Patent Information
- Application Number
- CN202310620889.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-30
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2043-05-30
AI Technical Summary
Existing bioluminescence imaging techniques lack effective small-molecule probes in detecting nitroreductase (NTR), and the NanoLuc-furimazine bioluminescence system has not been used to develop nitroreductase probes, limiting early diagnosis of disease and The development of treatment.
A nitro aromatic ring-substituted imidazolopyrazine compound was developed as a substrate of the NanoLuc bioluminescence system to detect nitroreductase. By binding to NanoLuc luciferase, selective reduction and imaging of NTR .
The nitroaroyl ring-substituted imidazolopyrazine compound exhibits good responsiveness in vitro and in vivo, can selectively reduce and detect NTR activity, broaden the application of NanoLuc bioluminescence technology and improve the potential for disease diagnosis and treatment.
Smart Images

Figure CN119060054A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of bioluminescent imaging, in particular to a nitroaromatic ring substituted imidazopyrazine compound and a preparation method and application thereof. Background Art
[0002] Various endogenous species in organisms (such as bacteria in the microenvironment of the body) play an important role in life, and the detection of active substances requires excellent imaging tools for visualization. Bioluminescence (BL) imaging, as a new imaging technology, has become an indispensable technology in biomedical research, and is currently the main strategy for studying and exploring life activities in living cells and organisms [1-2]. Compared with traditional fluorescence imaging technology, bioluminescence imaging relies on the enzymatic reaction of luciferase oxidizing its substrate to emit light, avoiding the interference and phototoxicity of exogenous excitation light, and can provide extremely high signal-to-noise ratio in imaging [3-4]. As a non-invasive, longitudinal tracking technology, bioluminescence imaging is widely used in the forefront of exploring life mechanisms, from sensitive cell analysis to bioluminescence-based molecular imaging [5-6].
[0003] Since DeLuca's laboratory first reported the cloning of firefly luciferase (FLuc, from Photinus pyralis) in Escherichia coli [7], the widespread application of bioluminescence has promoted the study of luciferase. As a result, researchers have discovered several luciferases and corresponding substrates from Oplophorus gracilirostris (OLuc) and Gaussia princeps (GLuc) [8-10]. For example, the cDNA clone of OLuc consists of two 35kDa subunits and two 19kDa subunits, and the bioluminescent activity is only associated with the smaller subunit (OLuc-19) [11-12]. However, the low expression and stability issues of this subunit protein limit its application. Mutagenesis optimization of this subunit enabled Promega scientists to obtain stable and high bioluminescent pair NanoLuc (NLuc) and the corresponding substrate furimazine
[13] . As a novel bioluminescent imaging platform, NLuc-furimazine can generate high-intensity, glow-type luminescent signals (signal half-life > 2h), and the bioluminescent intensity is more than 150 times higher than that of the traditional firefly luciferase and coelenterazine system
[13] . In addition, NonaLuc enzyme has the advantages of small size, high expression rate, and good physical stability, and is suitable for various fields such as medicine
[14] , biology
[15] , physics
[16] and multidisciplinary science[17-18].
[0004] Although some studies on the modification of corresponding substrates by deep-sea bioluminescent luciferase NanoLuc have been reported [19-25], there are still few small molecule probes developed based on the NLuc-furimazine bioluminescent system. In addition, to date, no research has used the NLuc-furimazine luminescent system to develop nitroreductase probes. Nitroreductase (NTR), as an important class of oxidoreductases in organisms, catalyzes nitroaromatic compounds to generate corresponding amino compounds in the presence of NADH or nicotinamide adenine dinucleotide phosphate (NADPH). Abnormal expression of NTR is closely related to a variety of disease processes. Therefore, accurate detection of NTR expression levels is of great significance for early diagnosis, disease monitoring and development of some special diagnosis and treatment technologies for various diseases [26-29]. To this end, the present invention has developed a series of NTR bioluminescent probes based on the NLuc-furimazine system to further promote the development of diagnosis and treatment methods for flavin protease-related diseases on the basis of broadening the application of NanoLuc bioluminescent technology. Summary of the invention
[0005] The purpose of the present invention is to provide a nitroaromatic ring substituted imidazopyrazine compound and its preparation method and application. The compound can be used as a probe for detecting nitroreductase, thereby broadening the application of NanoLuc bioluminescence technology.
[0006] To achieve the above object, the present invention provides the following technical solutions:
[0007] In a first aspect, the present invention provides a nitroaromatic ring substituted imidazopyrazine compound having the general formula (1):
[0008]
[0009] Among them, R 1 is H, OH, alkoxy, R 2 It is an arylmethyl group substituted by a nitro group.
[0010] In the above compounds, R 2 The aromatic ring in is a benzene ring or a heteroaromatic ring.
[0011] Preferably, the heteroaromatic ring includes but is not limited to a furan ring, a thiophene ring, a pyrrole ring, an imidazole ring, ...
[0012] Most preferably, R 2 Any one of the following groups:
[0013]
[0014] As a preferred embodiment, the compound is selected from:
[0015] Compound 1: 8-benzyl-2-(furan-2-ylmethyl)-3-((5-nitrofuran-2-yl)methoxy)-6-phenylimidazo[1,2-a]pyrazine;
[0016] Compound 2: 8-benzyl-2-(furan-2-ylmethyl)-3-((1-methyl-2-nitro-1H-imidazol-5-yl)methoxy)-6-phenylimidazo[1,2-a]pyrazine;
[0017] Compound 3: 8-benzyl-2-(furan-2-ylmethyl)-3-((1-methyl-5-nitro-1H-imidazol-2-yl)methoxy)-6-phenylimidazo[1,2-a]pyrazine;
[0018] Compound 4: 8-benzyl-2-(furan-2-ylmethyl)-3-((5-nitrothiophene-2-yl)methoxy)-6-phenylimidazo[1,2-a]pyrazine;
[0019] Compound 5: 8-benzyl-2-(furan-2-ylmethyl)-3-((2-nitrobenzyl)oxy)-6-phenylimidazo[1,2-a]pyrazine;
[0020] Compound 6: 8-benzyl-2-(furan-2-ylmethyl)-3-((4-nitrobenzyl)oxy)-6-phenylimidazo[1,2-a]pyrazine;
[0021] Compound 7: 3-(8-benzyl-2-(furan-2-ylmethyl)-3-((1-methyl-2-nitro-1H-imidazol-5-yl)methoxy)imidazo[1,2-a]pyrazin-6-yl)phenol.
[0022] In a second aspect, the present invention provides a method for preparing the compound as described above, the method comprising:
[0023] Under the protection of inert gas, protected or unprotected 8-benzyl-2-(furan-2-ylmethyl)-6-phenylimidazo[1,2-a]pyrazine-3(7H)-one is used as a raw material and reacted with a methyl bromide derivative under the action of potassium carbonate to obtain a compound represented by formula (1).
[0024] In a third aspect, the present invention provides the use of the compound as described above as a bioluminescent probe for detecting nitroreductase.
[0025] Preferably, the probe is used as a substrate for the NanoLuc bioluminescent system, for bioluminescent imaging studies, or for detecting drug effects.
[0026] In a fourth aspect, the present invention provides a kit for detecting nitroreductase, comprising the compound as described in any one of claims 1 to 5.
[0027] Compared with the prior art, the present invention has the following beneficial effects:
[0028] (1) The compound having the structure of formula (1) provided by the present invention can be used as a nitroreductase probe, exhibits good responsiveness in in vitro experiments, can be selectively reduced by NTR, and can detect and image NTR activity in vivo at the cellular level and animal level;
[0029] (2) The nitroreductase probes having the structure of formula (1) provided by the present invention can all be used as corresponding substrates of the NanoLuc bioluminescence system, thereby broadening the application of NanoLuc bioluminescence technology. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 The figure is a result diagram of the chemical stability test of the compound of the present invention;
[0031] Figure 2 This is a diagram showing the experimental results of the mechanism of action verification of the compound of the present invention as a nitroreductase probe;
[0032] Figure 3 The graph is a result of a bioluminescent signal experiment in which the compound of the present invention is used as a nitroreductase probe and incubated for different time periods in vitro;
[0033] Figure 4 This is a graph showing the concentration dependence experimental results of the compound of the present invention as a nitroreductase probe;
[0034] Figure 5 This is a diagram showing the results of a selectivity experiment of the compound of the present invention as a nitroreductase probe;
[0035] Figure 6 The figure is a cytotoxicity test result diagram of the compound of the present invention;
[0036] Figure 7 This is a diagram showing the results of a bioluminescent imaging experiment using the compound of the present invention as a nitroreductase probe in a bacterial solution;
[0037] Figure 8 This is a diagram showing the results of a bioluminescent imaging experiment using the compound of the present invention as a nitroreductase probe in an animal model;
[0038] Fig. 9 This is a graph showing the results of an experiment in which the compound of the present invention is used as a nitroreductase probe to detect the NTR activity of intestinal bacteria in mice. DETAILED DESCRIPTION
[0039] The following will be combined with the specific embodiments of the present invention and the accompanying drawings to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0040] In the description of the present invention, it should be noted that the terms "upper", "lower", "inner", "outer", "front end", "rear end", "two ends", "one end", "the other end" and the like indicate positions or positional relationships based on the positions or positional relationships shown in the drawings, and are only for the convenience of describing the present invention and simplifying the description, and do not indicate or imply that the device or element referred to must have a specific orientation, be constructed and operated in a specific orientation, and therefore cannot be understood as limiting the present invention. In addition, the terms "first" and "second" are used for descriptive purposes only and cannot be understood as indicating or implying relative importance.
[0041] In the description of the present invention, it should be noted that, unless otherwise clearly specified and limited, the terms "installed", "provided with", "connected", etc. should be understood in a broad sense. For example, "connected" can be a fixed connection, a detachable connection, or an integral connection; it can be a mechanical connection or an electrical connection; it can be a direct connection, or it can be indirectly connected through an intermediate medium, or it can be the internal communication of two components. For ordinary technicians in this field, the specific meanings of the above terms in the present invention can be understood according to specific circumstances.
[0042] In order to clearly understand the technical content of the present invention, the specific implementation method of the present invention is further described below in conjunction with specific embodiments.
[0043] Synthesis of Nitroreductase Probe
[0044] Example 1: Preparation of Intermediate 1c
[0045]
[0046] Under ice-water bath conditions, NaBH was added to a solution of 5-nitrofuran-2-carbaldehyde (705 mg, 5 mmol) in methanol (30 mL). 4 (378 mg, 10 mmol), and the resulting mixture was stirred at 0°C for 0.5 h. After the raw material 1a was consumed, water was added to quench, and the aqueous layer was extracted with EA. The combined organic layers were washed with anhydrous Na 2 SO 4 The residue was dried, concentrated under reduced pressure, and 465 mg (65%) of compound 1b was obtained by silica gel column chromatography (PE / EA=4 / 1). TLC (PE / EA=2 / 1): R f=0.23; 1 H NMR (500 MHz, CDCl 3 )δ7.28(d,J=3.7Hz,1H),6.55(d,J=3.7Hz,1H),4.70(s,2H),2.56(s,1H).
[0047] Under ice-water bath conditions, the hydroxymethyl derivative (1b) (3.5 mmol) was dissolved in dichloromethane (4 mL), and a solution of phosphorus tribromide (4.47 mmol) in dichloromethane (3 mL) was added dropwise to the above solution, and then stirred for 30-60 min. Water was added to quench, and the aqueous layer was extracted with DCM. The combined organic layers were washed with anhydrous Na 2 SO 4 The residue was dried, concentrated under reduced pressure, and chromatographed on a silica gel column (PE / EA=5 / 1) to give 339 mg (73%) of 2-(bromomethyl)-5-nitrofuran 1c. TLC (PE / EA=5 / 1): R f =0.33; 1 H NMR (500 MHz, CDCl 3 )δ7.27(d,J=3.7Hz,1H),6.62(d,J=3.7Hz,1H),4.46(s,2H); 13 C NMR (126 MHz, CDCl 3 )δ153.47,151.77,112.52,112.43,20.74.
[0048] Example 2: Preparation of intermediate 4c
[0049] According to the method described in 1c, 5-nitrothiophene-2-carboxaldehyde (785 mg, 5 mmol) and NaBH 4 (378 mg, 10 mmol) was used to prepare (5-nitrofuran-2-yl)methanol 4b (PE / EA=4 / 1, 556 mg, 0.35 mmol, 70%). TLC (PE / EA=2 / 1): R f =0.15; 1 H NMR (500 MHz, CDCl 3 )δ7.79(d,J=4.1Hz,1H),6.91(dd,J=4.0,1.0Hz,1H),4.85(s,2H). Then, 4b and PBr 3 (0.4 mL, 4.2 mmol) was prepared in DCM solution to give 2-(bromomethyl)-5-nitrofuran 4c (PE / EA=5 / 1, 633 mg, 85%). TLC (PE / EA=5 / 1): R f =0.53; 1H NMR (500 MHz, CDCl 3 )δ7.76(d,J=4.1Hz,1H),7.06(d,J=4.1Hz,1H),4.62(s,2H). 13 C NMR (126 MHz, CDCl 3 )δ151.77,148.38,128.46,127.14,24.65.
[0050] Example 3: Preparation of Intermediate 2b
[0051]
[0052] The hydroxymethyl derivative 2a (550 mg, 3.5 mmol) was dissolved in dichloromethane (20 mL) and the reaction was placed in an ice bath. Then, pyridine (0.83 mL, 10.5 mmol), SOCl 2 (0.77mL, 10.5mmol) in dichloromethane (10mL) solution was added dropwise and stirred at 0°C for 60min, and then the mixture was allowed to react overnight after the mixture was heated to room temperature. Water was added to quench the mixture, and the aqueous layer was extracted with DCM. The organic layers were combined and washed with anhydrous Na 2 SO 4 The residue was dried, concentrated under reduced pressure, and purified by silica gel column chromatography (PE:EA=1 / 1) to give 5-(chloromethyl)-1-methyl-2-nitro-1H-imidazole 2b (460 mg, 75%). TLC (PE / EA=1 / 1): R f =0.38; 1 H NMR (500 MHz, CDCl 3 )δ7.19(s,1H),4.63(s,2H),4.07(s,3H); 13 C NMR (126 MHz, CDCl 3 )δ146.46,132.83,128.57,34.26,33.93.
[0053] Example 4: Preparation of Intermediate 3b
[0054]
[0055] Following the synthesis of compound 2b, 2-(chloromethyl)-1-methyl-5-nitro-1H-imidazole 3b was prepared with a yield of 80%. TLC (PE / EA=1 / 1): R f =0.45; 1 H NMR (500 MHz, CDCl 3 )δ7.94(s,1H),4.67(s,2H),4.04(s,3H); 13C NMR (126 MHz, CDCl 3 )δ147.18,139.76,131.82,36.15,33.83.
[0056] Example 5: Preparation of probes 1-6
[0057]
[0058] General procedure for the synthesis of probes (1-6): Under nitrogen atmosphere, to a solution of Fz (133 mg, 0.35 mmol) in DMF (3.5 mL) were added methyl bromide (chloro) derivative (1.05 mmol) and K 2 CO 3 (1.05mmol). The mixture was stirred at room temperature for 8-10 hours. After the reaction was completed, water (30mL) was added to quench and extracted with EA (30mL×2). The combined organic layers were washed with brine and anhydrous Na 2 SO 4 Dry and concentrate. Use silica gel column (PE / EA) or preparative high performance liquid chromatography (CH 3 CN / H 2 O, flow rate 8 mL / min) to obtain probes 1-6.
[0059] 8-Benzyl-2-(furan-2-ylmethyl)-3-((5-nitrofuran-2-yl)methoxy)-6-phenylimidazo[1,2-a]pyrazine: prepared from Fz and 2-(bromomethyl)-5-nitrofuran by preparative HPLC (65% CH 3 CN / H 2 O) Probe 1 (103 mg, 58%) was purified as a yellow solid. 1 H NMR (500 MHz, CDCl 3 )δ7.78–7.74(m,2H),7.43–7.39(m,3H),7.38–7.33(m,3H),7.30–7.27(m,2H),7.25–7.22(m,1H),7.14(d,J=1.9Hz,1H),7.01(d,J=3.6H z,1H),6.14(dd,J=3.2,1.9Hz,1H),6.09(d,J=3.7Hz,1H),5.96(d,J=3.2Hz,1H),4.18–4.11(m,2H),3.35(q,J=15.1Hz,2H),3.29(s,2H); 13 C NMR (126 MHz, CDCl 3)δ180.85,158.32,153.48,151.32,149.70,148.24,142.06,135.76,134.78,133.16,129.52(×2),128.81(×2),,128.58,128 .43(×2),126.87,125.19(×2),112.37,111.73,110.39,108.83,108.66,74.47,39.51,35.30,34.62; HRMS(ESI)m / zcalc.for C 29 H 23 N 4 O 5 [M+H] + 507.1668, found 507.1671. HPLC purity 97.0%.
[0060] 8-Benzyl-2-(furan-2-ylmethyl)-3-((1-methyl-2-nitro-1H-imidazol-5-yl)methoxy)-6-phenylimidazo[1,2-a]pyrazine: prepared from Fz and 5-(chloromethyl)-1-methyl-2-nitro-1H-imidazole by preparative HPLC (58% CH 3 CN / H 2 O) was purified to obtain probe 2 (122 mg, 67%) as an off-white solid. 1 HNMR (500MHz, CDCl 3 )δ7.87–7.83(m,3H),7.61–7.58(m,2H),7.46(td,J=7.2,6.3,1.3Hz,2H),7.41–7.37(m,1H),7.34(d,J=1.8Hz,1H),7.29(t,J=7.7Hz,2H) ,7.21(d,J=7.3Hz,1H),7.11(s,1H),6.34(dd,J=3.3,1.9Hz,1H),6.18–6.12(m,1H),5.05(s,2H),4.59(s,2H),4.16(s,2H),4.03(s,3H); 13 C NMR (126 MHz, CDCl 3)δ153.34,151.80,146.62,141.63,139.30,137.72,136.48,136.24,132.46,131.77,130.62,129.71(×2),129.66,128 .95(×2),128.80,128.32(×2),126.55,126.20(×2),110.81,108.47,106.90,65.45,39.37,34.41,26.97; HRMS(ESI)m / z calc.for C 29 H 25 N 6 O 4 [M+H] + 521.1937, found 521.1937. HPLC purity 98.0%.
[0061] 8-Benzyl-2-(furan-2-ylmethyl)-3-((1-methyl-5-nitro-1H-imidazol-2-yl)methoxy)-6-phenylimidazo[1,2-a]pyrazine: Prepared using Fz and 2-(chloromethyl)-1-methyl-5-nitro-1H-imidazole as raw materials, and purified by silica gel column chromatography (PE / EA=2 / 1) to obtain probe 3 (136 mg, 75%) as an off-white solid. 1 HNMR (500MHz, CDCl 3 )δ8.03(s,1H),7.97(s,1H),7.92–7.88(m,2H),7.61–7.57(m,2H),7.46(dd,J =8.3,6.7Hz,2H),7.41–7.37(m,1H),7.34(dd,J=1.9,0.8Hz,1H),7.29(dd,J= 8.3,6.9Hz,2H),7.23–7.19(m,1H),6.35(dd,J=3.3,1.9Hz,1H),6.16(dd,J=3 .2,1.0Hz,1H),5.12(s,2H),4.59(s,2H),4.20(d,J=0.9Hz,2H),3.99(s,3H); 13 C NMR (126 MHz, CDCl 3)δ153.14,151.94,146.29,141.57,139.16,137.77,136.57,136.29,132.48,131.94,130.59,129.70(×2),128.86(×2) ,128.68,128.29(×2),126.50,126.23(×2),110.78,108.95,106.87,99.99,67.98,39.35,33.73,26.92; HRMS(ESI)m / z calc.for C 29 H 25 N 6 O 4 [M+H] + 521.1937, found 521.1939. HPLC purity 98.0%.
[0062] 8-Benzyl-2-(furan-2-ylmethyl)-3-((5-nitrothiophene-2-yl)methoxy)-6-phenylimidazo[1,2-a]pyrazine: prepared from Fz and 2-(bromomethyl)-5-nitrothiophene by preparative HPLC (65% CH 3 CN / H 2 O) Purification gave probe 4 (111 mg, 61%) as a yellow solid. 1 H NMR (500 MHz, CDCl 3 )δ7.75–7.72(m,2H),7.55(d,J=4.1Hz,1H),7.44–7.37(m,5H),7.34(ddd,J=7.7,5.4,2.5Hz,3H),7.30–7.28(m,2H),7.12(d,J=1 .7Hz,1H),6.61(d,J=4.1Hz,1H),6.12(dd,J=3.2,1.9Hz,1H),5.92(d,J=3.2Hz,1H),4.21(s,2H),3.47–3.32(m,2H),3.27(s,2H); 13 C NMR (126 MHz, CDCl 3)δ180.69,158.39,151.15,149.84,148.28,144.56,142.01,135.60,134.60,133.18,129.65(×2),128.80(×2),128.64 ,128.54(×2),128.16,127.15,127.01,125.12(×2),110.36,108.72,108.37,75.71,39.64,36.76,35.41; HRMS(ESI)m / z calc.for C 29 H 23 N 4 O 4 S[M+H] + 523.1440, found 523.1439. HPLC purity 96.0%.
[0063] 8-Benzyl-2-(furan-2-ylmethyl)-3-((2-nitrobenzyl)oxy)-6-phenylimidazo[1,2-a]pyrazine: prepared using Fz and 1-(bromomethyl)-2-nitrobenzene as raw materials, and purified by silica gel column chromatography (PE / EA=3 / 1) to obtain probe 5 (143 mg, 79%) as an off-white solid. 1 H NMR (500 MHz, CDCl 3 )δ8.17(dd,J=8.2,1.3Hz,1H),8.08(s,1H),7.93–7.90(m,2H),7.85(dd,J=7.8,1.3Hz, 1H),7.74(dd,J=7.5,1.3Hz,1H),7.63–7.60(m,2H),7.57(td,J=7.9,1.4Hz,1H),7.45( dd,J=8.4,6.9Hz,2H),7.38(d,J=7.3Hz,1H),7.32–7.27(m,3H),7.23–7.19(m,1H),6.2 7(dd,J=3.2,1.9Hz,1H),6.13(d,J=3.1Hz,1H),5.45(s,2H),4.61(s,2H),4.22(s,2H); 13 C NMR (126 MHz, CDCl 3)δ152.98,152.04,147.23,141.55,138.86,137.95,136.98,136.79,134.09,132.40,131.90,130.37,129.74(×2),129.39,129. 38,128.81(×2),128.52,128.29(×2),126.47,126.28(×2),125.13,110.55,109.08,106.77,73.60,39.34,26.90; HRMS(ESI)m / z calc.for C 31 H 25 N 4 O 4 [M+H] + 517.1876, found 517.1875. HPLC purity 97.0%.
[0064] 8-Benzyl-2-(furan-2-ylmethyl)-3-((4-nitrobenzyl)oxy)-6-phenylimidazo[1,2-a]pyrazine: prepared using Fz and 1-(bromomethyl)-4-nitrobenzene as raw materials, and purified by silica gel column chromatography (PE / EA=3 / 1) to obtain probe 6 (148 mg, 82%) as an off-white solid. 1 H NMR (500 MHz, CDCl 3 )δ8.27–8.23(m,2H),7.88(s,1H),7.84–7.81(m,2H),7.62–7.59(m,2H),7.57–7.54(m,2H),7.46–7.42(m,2H),7.40–7.35(m,1H),7.33 –7.27(m,3H),7.24–7.19(m,1H),6.32(dd,J=3.2,1.9Hz,1H),6.13(dd,J=3.2,1.0Hz,1H),5.13(s,2H),4.59(s,2H),4.19–4.17(m,2H); 13 C NMR (126 MHz, CDCl 3)δ153.13,152.07,148.15,142.66,141.51,138.92,137.86,136.94,136.69,132.40,130.36,129.74(×2),128.85(×2),128. 62,128.61(×2),128.27(×2),126.48,126.19(×2),124.00(×2),110.63,108.77,106.79,75.60,39.35,26.88; HRMS(ESI)m / z calc.for C 31 H 25 N 4 O 4 [M+H] + 517.1876, found 517.1877. HPLC purity 98.0%.
[0065] Example 6: Preparation of probe 7
[0066]
[0067] 8-Benzyl-6-(3-((tert-butyldimethylsilyl)oxy)phenyl)-2-(furan-2-ylmethyl)imidazo[1,2-a]pyrazin-3(7H)-one (7a): Compound 7a was obtained according to a previously reported method
[21] . 1 H NMR (500 MHz, CDCl 3 )δ7.78(d,J=3.8Hz,1H),7.74(d,J=1.6Hz,1H),7.71(s,1H),7.57–7.54(m,2H),7.45(s,1H),7.40(dd,J=7.9,1.4Hz,1H),7.35–7.31(m,3H), 7.29(d,J=7.9Hz,1H),7.24(d,J=7.5Hz,1H),6.83(dd,J=8.0,2.4Hz,1H),6.74(dd,J=3.8,1.6Hz,1H),4.38(s,2H),1.01(s,9H),0.22(s,6H).
[0068] 3-(8-Benzyl-2-(furan-2-ylmethyl)-3-((1-methyl-2-nitro-1H-imidazol-5-yl)methoxy)imidazo[1,2-a]pyrazin-6-yl)phenol: Under nitrogen protection, 7a (179 mg, 0.35 mmol), 5-(chloromethyl)-1-methyl-2-nitro-1H-imidazole (2b) (184 mg, 1.05 mmol) and K 2 CO 3(145 mg, 1.05 mmol) was dissolved in 5 mL of DMF and reacted overnight at room temperature. After the reaction was completed, quenched with 30 mL of water, extracted with ethyl acetate (2×30 mL), and the organic phases were combined and washed with anhydrous Na 2 SO 4 The crude product was dried and concentrated under reduced pressure to obtain a reddish brown solid. The crude product was dissolved in 10 mL of methanol solution, 0.5 mL of HCl (6 M) solution was added and the reaction was stirred at room temperature for 1 hour. After the reaction was completed, 30 mL of water was added and the mixture was poured into a separatory funnel. The aqueous layer was extracted with dichloromethane, and the organic layers were combined and purified by anhydrous Na 2 SO 4 The crude product was purified by preparative high performance liquid chromatography (55% CH 3 CN / H 2 O, flow rate 8 mL / min) to obtain probe 7 (118 mg, 63%) as a yellow solid. 1 HNMR (500MHz, CDCl 3 )δ7.81(s,1H),7.53–7.48(m,2H),7.38–7.33(m,2H),7.29(d,J=1.8Hz,1H ),7.24(t,J=7.9Hz,1H),7.18(t,J=7.5Hz,2H),7.13–7.09(m,1H),7.06(s, 1H), 6.84 (dd, J=8.0, 2.4Hz, 1H), 6.29 (dd, J=3.2, 1.9Hz, 1H), 6.11 (d, J=3. 2Hz,1H),5.71(s,1H),5.00(s,2H),4.53(s,2H),4.14(s,2H),3.94(s,3H); 13 C NMR (126 MHz, CDCl 3 )δ157.00,152.96,151.63,146.40,141.63,139.02,137.74,137.56,136.35,132.41,132.03,130.64,130.15,129.58(×2) ,129.46,128.29(×2),126.51,118.06,116.16,113.17,110.81,108.77,106.99,65.43,39.24,34.39,26.77; HRMS(ESI)m / z calc.forC 29 H 29 N 6 O 5 [M+H] +537.1886, found 537.1883. HPLC purity 97.0%.
[0069] Activity evaluation of nitroreductase probe
[0070] Reagents and Materials
[0071] 50 mM Tris-HCl (pH=7.40) buffer solution a: purchased from Shanghai Yuanye Biotechnology Co., Ltd.
[0072] Preparation of 50 mM Tris-HCl (containing 0.5 mM NADH, pH = 7.40) buffer solution b: Dissolve 70.94 mg of NADH disodium salt in 200 mL of MiliQ ultrapure water and prepare it for use immediately.
[0073] Preparation of nitroreductase probe solution: Weigh a certain amount of nitroreductase probe, dissolve it in DMSO, prepare a 25mM concentrated stock solution, dilute it with buffer solution to the required concentration, and prepare it before use.
[0074] Preparation of nitroreductase solution: Dissolve 1 mg of nitroreductase in 1 mL of PBS on ice and dilute to the desired concentration with buffer solution.
[0075] Escherichia coli strain BL21(DE3) was from Sigma-Aldrich (St. Louis, MO).
[0076] NanoLuc luciferase was made in-house in the laboratory: NanoLuc was constructed onto the pMKH vector, the pMKH-NanoLuc plasmid was transformed into the E. coli BL21 (DE3) strain, the strain was cultured and protein expression was induced, and then the target protein was purified.
[0077] Example 7: Chemical stability test of probe
[0078] To test the chemical stability of the probe, a 500 μM NTR probe or Fz ethanol solution was first prepared and stored in the dark at 25°C for a certain period of time (0-48 h). The changes in the content were monitored by HPLC and the chromatograms were recorded at an absorbance of 254 nm. Figure 1 The graph shows the changes in the content of the probe in ethanol solution (500 μM) after storage at 25° C. for a certain period of time (0-48 h).
[0079] Example 8: Verification of the action mechanism of the probe
[0080] Add 100 μL of probe 7 solution (5 mM) and 900 μL of nitroreductase (10 μg / mL) in Tris-HCl buffer to one EP tube, mix thoroughly, and incubate at 37°C for 5 hours. At the same time, add 1000 μL of probe 7 (500 μM) solution or luciferase (250 μM) solution to the EP tube as a standard sample.
[0081] After filtering with millipore, the samples were transferred to high performance liquid phase vials and analyzed using Waters-2695 HPLC. Figure 2 ), in the presence of NADH, probe 7 can be reduced by nitroreductase, and the retention time of the reduction product in the spectral peak coincides with the retention time of fluorescein. Therefore, the reduction mechanism of the probe is confirmed, and more in-depth activity testing can be performed.
[0082] Among them Figure 2 In the graph, curve S1 is probe 7 (500 μM) + NTR (5 μg / mL) + NADH (500 μM), S2 is fluorescein (250 μM), and S3 is probe 7 (500 μM).
[0083] Example 9: Experiment on the dependence of probe bioluminescence intensity on time
[0084] The time-dependent assay was measured in Tris-HCl buffer. The probe concentrated stock solution (25 mM) was diluted to a concentration of 25 μM with Tris-HCl buffer. 50 μL of the diluted probe solution and 50 μL of 5 μg / mL nitroreductase solution (containing 0.5 mM NADH) were added to each well of a 96-well plate (WHB, black) and incubated at 37°C for 30, 40, 60 or 90 min (three replicates per group). After incubation, 50 μL of NanoLuc luciferase (10 μg / mL) in Tris-HCl buffer was added to each well, and the bioluminescence intensity of each well was immediately measured with an AniView100 multi-mode animal live imager with an exposure time of 5 s. Figure 3 The bioluminescent signal response graphs of the probe and nitroreductase incubated for different time in vitro are shown, e.g. Figure 3 As shown, with the increase of incubation time, the bioluminescence signal gradually increased, reached a maximum value at 30 min, and decreased slightly at 90 min.
[0085] Example 10: Experiment on the dependence of probe bioluminescence intensity on nitroreductase concentration
[0086] The concentration dependence experiment of nitroreductase probe was carried out in Tris-HCl buffer system.
[0087] First, the prepared nitroreductase was diluted with buffer solution b to a final concentration of 0 μg / mL, 0.039 μg / mL, 0.078 μg / mL, 0.156 μg / mL, 0.312 μg / mL, 0.625 μg / mL, 1.25 μg / mL, 2.5 μg / mL, 5 μg / mL, and 10 μg / mL. Then, 50 μL of probe solution (25 μM) and 50 μL of nitroreductase solution of different concentrations were added to the 96-well full black plate in sequence, mixed evenly, and incubated on a constant temperature oscillator at 37°C for 30 minutes (three replicate wells were set for each group). Subsequently, 50 μL of NanoLuc luciferase (10 μg / mL) solution was added to each well, and the bioluminescence intensity of each well was immediately measured with the AniView100 multi-mode animal live imager, with an exposure time of 5 s. Relative luminescence intensity = number of photons emitted by the experimental group [p / s / cm2 / sr] / number of photons emitted by the control group [p / s / cm2 / sr]. Figure 4 The sensitivity test results of the probe are shown, where Figure 4 A shows the bioluminescence imaging after the probe was incubated with different concentrations of NTR; Figure 4 B shows the relative bioluminescence intensity of probes 1-7 after incubation with different concentrations of NTR compared with the blank group; Figure 4 C shows the relationship between NTR concentration and relative bioluminescence intensity of probe 7 at 0-5 μg / mL; Figure 4 D shows the linear relationship between NTR concentration and relative bioluminescence intensity of probe 7 at 0-0.625 μg / mL (mean ± SD, n = 3). Figure 4 ), with the increase of NTR reductase concentration, the bioluminescent signals of all probes gradually increased. When CNTR = 5 μg / mL, the bioluminescent intensity of probes 1-7 increased by about 20 times, 770 times, 320 times, 40 times, 20 times, 280 times, and 560 times compared with the blank ( Figure 4 B). In the range of 0-0.625 μg / mL, the relative bioluminescence intensity of probe 7 is linearly related to the concentration of NTR, with a detection limit of 0.016 μg / mL, and can be used to quantitatively detect the content of NTR in aqueous solution.
[0088] Example 11: Probe Selectivity Test for Nitroreductase
[0089] Likewise, selectivity experiments for the nitroreductase probe were performed in a Tris-HCl buffer system.
[0090] First, 50 μL of diluted probe solution (25 μM) was added to each well of a 96-well plate. Subsequently, 50 μL of different reducing substances, including nitroreductase (10 μg / mL) + NADPH (0.5 mM), nitroreductase (10 μg / mL), NADPH (0.5 mM), reduced glutathione (GSH, 1000 μM), cysteine (Cys, 1000 μM), glutamate (Glu, 1000 μM), sodium ascorbate (VcNa, 1000 μM) and Tris-HCl solution of sodium hydrosulfide (NaSH, 1000 μM) were added to the probe solution (three replicate wells were set up in each group). After incubation at 37°C for 30 min, 50 μL of NanoLuc luciferase (10 μg / mL) solution was added to each well, and the bioluminescence intensity of each well was immediately measured using an AniView100 multi-mode animal in vivo imager with an exposure time of 5 s. The control group only had the probe and buffer solution. Figure 5 The results of the probe selectivity experiment are shown, where Figure 5 A shows the bioluminescence imaging of the probe and related substances; Figure 5 B shows the relative bioluminescence intensity of probes 1-7 and related substances compared with the blank group (mean±SD, n=3, *p<0.0001). Figure 5 ), compared with the control group, the bioluminescence intensity was significantly enhanced when the probe was co-incubated with NTR-NDAH; under other reducing conditions, the bioluminescence intensity was almost unchanged. This shows that the probe is more sensitive to the NTR-NADH system and is easily reduced to fluorescein.
[0091] Example 12: Probe cytotoxicity test
[0092] LX2 cells in the logarithmic growth phase were digested and inoculated into 96-well plates (5*10 4 / well), culture until adherence, discard the old culture medium, add complete culture medium (DEME+10% FBS+0.1% double antibody) containing the compound to be tested, and incubate at 37°C, 5% CO 2 After 24 h of incubation, 10 uL of CCK-8 solution (Biyuntian) was added to each well, and the incubation continued for 1 h. The UV absorbance was measured at 450 nm. Figure 6 The CCK8 method was used to detect the effects of different concentrations of probes 2 and 7 (10 μM, 20 μM) on cell viability after incubation with LX2 cells for 24 h (mean±SD, n=3).
[0093] Example 13: Application of probes at the cellular level
[0094] E. coli BL21 stored at -80°C was streaked on a plate for 12 h, and a single clone was picked and inoculated into 50 mL of liquid LB medium (C Kan =100 μg / mL), culture at 37°C, 180 rpm until the OD value of the bacterial solution reaches 0.6, set the shaking temperature to 16°C, continue culturing for 2 h, then add IPTG to a final concentration of 0.2 mM, and induce protein expression at 16°C, 180 rpm for 12-16 h.
[0095] Add 50 μL of probe solution (25 μM) and 50 μL of E. coli solution (0-10 μM) suspended in LB to the 96-well plate. 8 Bacteria / mL) were added and then incubated at 37°C. Afterwards, the bioluminescence intensity of each well was measured by the Aniview100 IVIS imaging system instrument with an exposure time of 5s. In addition, the NTR inhibitor assay experiment was to pre-treat the LB suspension of E. coli with or without dicoumarol (0.1mM) for 12h. Afterwards, the suspension was treated with 25μM probe 2 or 7 for 30min. The bioluminescence measurement of the bacterial solution was measured using EnVision Multimode Microplate Reader (PerkinElmer, USA). Figure 7 The experimental results of bioluminescence imaging of the probe in bacterial solution are shown. Figure 7 A shows the curve of bioluminescence intensity of the probe co-incubated with bacterial solution over time; Figure 7 B shows the probes were respectively attached to E.ColiNLuc + E.ColiNLuc - Bioluminescent signal of bacterial incubation; Figure 7 C shows the relative bioluminescence intensity with or without inhibitor pretreatment before the probe was incubated with the bacterial solution; Figure 7 D shows the bioluminescence intensity after the probe was incubated with different amounts of bacterial solution (mean±SD, n=3, ***p<0.001). Figure 7 As shown in A, the bioluminescent signal value is the highest when the probe is co-incubated with the bacterial solution for 30 minutes, and the bioluminescent intensity slowly weakens as time goes by. The probe is compared between different E. coli strains, such as Figure 7 As shown in B, compared with E. coli Luc- + Significant bioluminescent signals were detected. Moreover, the signal intensity of the bacterial solution treated with probes 2 and 7 was relatively high. Compared with Fz, the luminescent signals of 2 and 7 were comparable to that of Fz after 30 min of incubation ( Figure 7C), and as the number of bacteria decreases, the bioluminescence intensity decreases. The anticoagulant dihydroxycoumarin is an effective inhibitor of many flavin enzymes. The bioluminescence intensity of the group without coumarin is set to 1. After the addition of coumarin pretreatment, the bioluminescence intensity of the bacterial solution decreased significantly ( Figure 7 D). The results showed that the probe had good bioluminescence activity at the cellular level, demonstrating the potential application of the probe in luminescence imaging at the cellular level.
[0096] Example 14: Application of probes at the animal level
[0097] The bacteria were incubated in a 37 °C incubator until the OD reached 0.04 in LB medium containing 100 μg / mL Kan. 600 When the p-value reached 0.6, the culture was harvested by centrifugation (4000×g, 10min) and washed three times in PBS. After washing, the bacteria were resuspended in PBS. In order to obtain a relatively accurate luminescent signal, the hair on the hind legs of BALB / c mice was removed before modeling, and then 50 μL of bacteria suspended in PBS were directly injected into the quadriceps femoris at a depth of about 5 mm. (The concentration range of the bacterial suspension used for injection was 10 6 Up to 10 8 Bacteria / mL). One hour after bacterial injection, 200 μL of 10 mM probe or 200 μL of 10 mM Fz were injected IP. For in vivo experiments involving different concentrations of probe, the concentration of NCL probe injected was 200 μL of 1 mM or 10 mM solution. After the injection of the probe, the mice were imaged for bioluminescence at regular intervals. Figure 8 The experimental results of bioluminescence imaging of the probe in animal models are shown. Figure 8 A is the activity of probes 2 (1 mg / mouse) and 7 (1 mg / mouse) against infected bacteria (10 8 The results of bioluminescence imaging of model mice with 100% leucocytes and 100% leucocytes were obtained. Figure 8 B is the bioluminescence imaging result of the mouse bacterial infection model after injection of probe 7 (1 mg / mouse) or Fz (0.76 mg / mouse); Figure 7 C is the effect of probe 7 (1 mg / mouse) on infection with different amounts of bacterial solution (10 6 -10 8 The results of bioluminescence intensity determination of model mice containing 1000 bacteria / mL; Figure 7 D is the injection of different concentrations (0.1mg / mouse or 1mg / mouse) of probe 7 pairs of infected bacteria (10 8 The results of bioluminescence imaging of model mice with 100% leucocytes and 100% leucocytes (n=4). Figure 8As shown in A, the bioluminescent signal of probe 7 is significantly higher than that of probe 2, indicating that probe 7 is more suitable for in vivo imaging in animals. At 30 minutes after probe injection, obvious bioluminescent signals were detected, and then gradually increased to 90 minutes to reach a plateau. The signal intensity did not show a significant attenuation until 4 hours, and was related to the amount of injected probe and the amount of infected bacteria ( Figure 8 A, D). Compared with Fz, the bioluminescence intensity in the animals injected with probe 7 was slightly lower, but the signal decayed faster in the Fz group and was consistent with that in the probe 7 group at 2 h ( Figure 8 B) The above results indicate that probe 7 has a good imaging effect in animals and can be used to detect relevant models of bacterial infection.
[0098] Example 15: Probe for detecting NTR activity of intestinal bacteria
[0099] To measure the nitroreductase activity of the mouse intestinal microbiota, fresh feces from mice were collected, weighed, and then suspended in PBS at a ratio of 1:5 (g / ml). After mixing, magnetic beads were added and vortexed, and then centrifuged at 4°C (200×g, 10min) to obtain an intestinal bacterial suspension. After that, the bacterial strains were washed twice in PBS, lysed, centrifuged (8000×g, 5min, 4°C), and the supernatant was removed. The cells were washed once with Tris buffer (pH 7.4), centrifuged at 8000×g, 4°C for 5min, and the supernatant was removed. The bacterial pellet was resuspended in Tris buffer, homogenized to break the bacteria, and centrifuged to obtain the supernatant (15000×g, 15min, 4°C). After the supernatant was treated with 12.5μM probe 7 for 30min (six samples per group), 50μL of NanoLuc luciferase (10μg / mL) solution was added, and the bioluminescence intensity of the reaction solution was immediately measured by EnVision Multimode Microplate Reader (PerkinElmer). The standard curve was obtained by incubating probe 7 with different concentrations (0 μg / mL, 0.039 μg / mL, 0.078 μg / mL, 0.156 μg / mL, 0.312 μg / mL, 0.625 μg / mL) of nitroreductase. Fig. 9 The results of the detection of NTR activity of mouse intestinal bacteria by probe 7 are shown. Fig. 9 A shows the standard curve of the luminescence intensity of the probe versus the NTR concentration; Fig. 9 B shows the results of the NTR activity test of intestinal bacteria in mice (HFD vs ND, ***P<0.001, n=6). Fig. 9 As shown in the figure, a high-fat diet changes the structure of intestinal flora. Compared with the ND group, the intestinal NTR activity of the HFD group was significantly higher, and the difference was significant (***p<0.001). Therefore, a high-fat diet can change the intestinal flora and increase the activity of NTR.
[0100] The matters not described in detail in the present invention are all known technologies to those skilled in the art.
[0101] Finally, it should be noted that the above specific implementation methods are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified and replaced by equivalents without departing from the spirit and scope of the technical solution of the present invention, which should be included in the scope of the claims of the present invention.
[0102] References
[0103] [1]ZMKaskova,ASTsarkova,IVYampolsky,1001lights:Luciferins,luciferases,their mechanisms of action and applications in chemical analysis,biology and medicine,Chem.Soc.Rev.45(2016)6048-6077.
[0104] [2] LFGreer 3rd, AASzalay, Imaging of light emission from the expression of luciferases in living cells and organisms: a review, Luminescence. 17 (2002) 43-74.
[0105] [3] JAPrescher, CHContag, Guided by the light: visualizing biomolecular processes in living animals with bioluminescence, Curr. Opin. Chem. Biol. 14 (2010) 80-89.
[0106] [4]DKWelsh,SAKay,Bioluminescence imaging in living organisms,Curr.Opin.Biotechnol.16(2005)73-78.
[0107] [5]C.G.England,E.B.Ehlerding,W.Cai,NanoLuc:A Small Luciferase IsBrightening Up the Field ofBioluminescence,Bioconjug.Chem.27(2016)1175-1187.
[0108] [6]S.Iwano,M.Sugiyama,H.Hama,A.Watakabe,N.Hasegawa,T.Kuchimaru,K.Z.Tanaka,M.Takahashi,Y.Ishida,J.Hata,S.Shimozono,K.Namiki,T.Fukano,M.Kiyama,H.Okano,S.Kizaka-Kondoh,T.J.McHugh,T.Yamamori,H.Hioki,S.Maki,A.Miyawaki,Single-cell bioluminescence imaging of deep tissue in freelymoving animals,Science.359(2018)935-939.
[0109] [7]L.J.Kricka,F.R.Leach,In memoriam Dr Marlene DeLuca.1987O.M.SmithLecture.Firefly luciferase:mechanism ofaction,cloning and expression oftheactive enzyme,J.Biolumin.Chemilumin.3(1989)1-5.
[0110] [8]I.Yamaguchi,Oplophorus oxyluciferin and a model luciferin compoundbiologically active with Oplophorus luciferase,Biochem.J.151(1975)9-15.
[0111] [9]O.Shimomura,T.Masugi,F.H.Johnson,Y.Haneda,Properties and reactionmechanism ofthe bioluminescence system ofthe deep-sea shrimp Oplophorusgracilorostris,Biochemistry.17(1978)994-998.
[0112]
[10] B.A.Tannous,D.E.Kim,J.L.Fernandez,R.Weissleder,X.O.Breakefield,Codon-optimized Gaussia luciferase cDNA for mammalian gene expression inculture and in vivo,Mol.Ther.11(2005)435-443.
[0113]
[11] S.Inouye,K.Watanabe,H.Nakamura,O.Shimomura,Secretional luciferaseofthe luminous shrimp Oplophorus gracilirostris:cDNA cloning of a novelimidazopyrazinone luciferase(1),FEBS Lett.481(2000)19-25.
[0114]
[12] O.Shimomura,T.Masugi,F.H.Johnson,Y.Haneda,Properties and reactionmechanism ofthe bioluminescence system ofthe deep-sea shrimp Oplophorusgracilorostris,Biochemistry.17(1978)994-998.
[0115]
[13] M.P.Hall,J.Unch,B.F.Binkowski,M.P.Valley,B.L.Butler,M.G.Wood,P.Otto,K.Zimmerman,G.Vidugiris,T.Machleidt,M.B.Robers,H.A.Benink,C.T.Eggers,M.R.Slater,P.L.Meisenheimer,D.H.Klaubert,F.Fan,L.P.Encell,K.V.Wood,Engineeredluciferase reporter from a deep sea shrimp utilizing a novelimidazopyrazinone substrate,ACS.Chem.Biol.7(2012)1848-1857.
[0116]
[14] I.Pavlinov,M.Salkovski,L.N.Aldrich,Beclin 1-ATG14L Protein-Protein Interaction Inhibitor Selectively Inhibits Autophagy throughDisruption ofVPS34 Complex I,J.Am.Chem.Soc.142(2020)8174-8182.
[0117]
[15] A.S.Dixon,M.K.Schwinn,M.P.Hall,K.Zimmerman,P.Otto,T.H.Lubben,B.L.Butler,B.F.Binkowski,T.Machleidt,T.A.Kirkland,M.G.Wood,C.T.Eggers,L.P.Encell,K.V.Wood,NanoLuc Complementation Reporter Optimized for AccurateMeasurement of Protein Interactions in Cells,ACS.Chem.Biol.11(2016)400-408.
[0118]
[16] N.C.Dale,E.K.M.Johnstone,C.W.White,K.D.G.Pfleger,NanoBRET:TheBright Future ofProximity-BasedAssays,Front.Bioeng.Biotechnol.7(2019)56.
[0119]
[17] H.Shigeto,T.Ikeda,A.Kuroda,H.Funabashi,ABRET-based homogeneousinsulin assay using interacting domains in the primary binding site of theinsulin receptor,Anal,Chem.87(2015)2764-2770.
[0120]
[18] K.Krawczyk,S.Xue,P.Buchmann,G.Charpin-El-Hamri,P.Saxena,M.D.Hussherr,J.Shao,H.Ye,M.Xie,M.Fussenegger,Electrogenetic cellular insulinrelease for real-time glycemic control in type 1 diabetic mice,Science.368(2020)993-1001.
[0121]
[19] C.Yan,L.Du,M.Li,Novel NanoLuc-type substrates with various C-6substitutions,Bioorg.Med.Chem.Lett.30(2020)127085.
[0122]
[20] J.Li,X.Wang,G.Dong,C.Yan,Y.Cui,Z.Zhang,L.Du,M.Li,Novel furimazinederivatives for nanoluciferase bioluminescence with various C-6 and C-8substituents,Org,Biomol.Chem.19(2021)7930-7936.
[0123]
[21] Y.Su,J.R.Walker,T.P.Smith,L.X.Liu,M.P.Hall,L Labanieh,R Hurst,D.C.Wang,L.P.Encell,N Kim,F Zhang,M.A.Kay,K.M.Casey,R.G.Majzner,J.R.Cochran,C.L.Mackall,T.A.Kirkland,M.Z.Lin,Novel NanoLuc substrates enable bright two-population bioluminescence imaging in animals,Nat.Methods.17(2020)852-860.
[0124]
[22] Y.Su,J.R.Walker,M.P.Hall,M.A.Klein,X.Wu,L.P.Encell,K.M.Casey,L.X.Liu,G.Hong,M.Z.Lin,T.A.Kirkland,An optimized bioluminescent substrate fornon-invasive imaging in the brain,Nat.Chem.Biol.(2023).DOI:10.1038 / s41589-023-01265-x.
[0125]
[23] M.Hattori,G.Kawamura,R.Kojima,M.Kamiya,Y.Urano,T.Ozawa,ConfocalBioluminescence Imaging for Living Tissues with a Caged Substrate ofLuciferin,Anal.Chem.88(2016):6231-6238.
[0126]
[24] Y.Mizui,M.Eguchi,M.Tanaka,Y.Ikeda,H.Yoshimura,T.Ozawa,D.Citterio,Y.Hiruta,Long-term single cell bioluminescence imaging with C-3 positionprotected coelenterazine analogues,Org.Biomol.Chem.19(2021)579-586.
[0127]
[25] M.Orioka,M.Eguchi,Y.Mizui,Y.Ikeda,A.Sakama,Q.Li,H.Yoshimura,T.Ozawa,D.Citterio,Y.Hiruta,A Series of Furimazine Derivatives for SustainedLive-Cell Bioluminescence Imaging and Application to the Monitoring ofMyogenesis at the Single-Cell Level,Bioconjug.Chem.33(2022)496-504.
[0128]
[26] D.W.Bryant,D.R.McCalla,M.Leeksma,P.Laneuville,Type Initroreductases of Escherichia coli,Can.J.Microbiol.(1981)81-86.
[0129]
[27] S.Kitamura,N.Narai,K.Tatsumi,Studies on bacterialnitroreductases.Enzymes involved in reduction ofaromatic nitro compounds inEscherichia coli,J.Pharmacobiodyn.6(1983)18-24.
[0130]
[28] M.D.Roldán,E.Pérez-Reinado,F.Castillo,C.Moreno-Vivián,Reductionof polynitroaromatic compounds:the bacterial nitroreductases,FEMS.Microbiol.Rev.32(2008)474-500.
[0131]
[29] E.Akiva,J.N.Copp,N.Tokuriki,P.C.Babbitt,Evolutionary andmolecular foundations ofmultiple contemporary functions ofthe nitroreductasesuperfamily,Proc.Natl.Acad.Sci.U S A.114(2017)E9549-E9558。
Claims
1. A nitroaromatic ring substituted imidazopyrazine compound, characterized in that: The compound has the general formula (1): Among them, R 1 is H, OH, alkoxy, R 2 It is an arylmethyl group substituted by a nitro group.
2. The nitroaromatic ring substituted imidazopyrazine compound according to claim 1, characterized in that: R 2 The aromatic ring in is a benzene ring or a heteroaromatic ring.
3. The nitroaromatic ring substituted imidazopyrazine compound according to claim 2, characterized in that: The heteroaromatic ring includes, but is not limited to, a furan ring, a thiophene ring, a pyrrole ring, an imidazole ring, a thiazole ring, and an oxazole ring.
4. The nitroaromatic ring substituted imidazopyrazine compound according to claim 3, characterized in that: R 2 Any one of the following groups:
5. The nitroaromatic ring substituted imidazopyrazine compound according to claim 1, characterized in that: The compound is selected from: Compound 1: 8-benzyl-2-(furan-2-ylmethyl)-3-((5-nitrofuran-2-yl)methoxy)-6-phenylimidazo[1,2-a]pyrazine; Compound 2: 8-benzyl-2-(furan-2-ylmethyl)-3-((1-methyl-2-nitro-1H-imidazol-5-yl)methoxy)-6-phenylimidazo[1,2-a]pyrazine; Compound 3: 8-benzyl-2-(furan-2-ylmethyl)-3-((1-methyl-5-nitro-1H-imidazol-2-yl)methoxy)-6-phenylimidazo[1,2-a]pyrazine; Compound 4: 8-benzyl-2-(furan-2-ylmethyl)-3-((5-nitrothiophene-2-yl)methoxy)-6-phenylimidazo[1,2-a]pyrazine; Compound 5: 8-benzyl-2-(furan-2-ylmethyl)-3-((2-nitrobenzyl)oxy)-6-phenylimidazo[1,2-a]pyrazine; Compound 6: 8-benzyl-2-(furan-2-ylmethyl)-3-((4-nitrobenzyl)oxy)-6-phenylimidazo[1,2-a]pyrazine; Compound 7: 3-(8-benzyl-2-(furan-2-ylmethyl)-3-((1-methyl-2-nitro-1H-imidazol-5-yl)methoxy)imidazo[1,2-a]pyrazin-6-yl)phenol.
6. The method for preparing the compound according to any one of claims 1 to 5, characterized in that: The method comprises: Under the protection of inert gas, protected or unprotected 8-benzyl-2-(furan-2-ylmethyl)-6-phenylimidazo[1,2-a]pyrazine-3(7H)-one is used as a raw material and reacted with a methyl bromide derivative under the action of potassium carbonate to obtain a compound represented by formula (1).
7. The use of a compound according to any one of claims 1 to 5, characterized in that Used as a bioluminescent probe for the detection of nitroreductase.
8. The use according to claim 7, characterized in that The probe is used as a substrate for the NanoLuc bioluminescent system, for bioluminescent imaging studies, or for detecting drug effects.
9. A kit for detecting nitroreductase, characterized in that: The method comprises the compound according to any one of claims 1 to 5, NanoLuc luciferase, NADH and a 50 mM Tris-HCl (pH=7.40) buffer solution.
Citation Information
Patent Citations
Benzothiazole derivative as nitroreductase fluorescent probe and application thereof
CN110951484A
Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins
WO2018197727A1
Serum stable pro-coelenterazine analogues
WO2019010094A1
